Company profile: NovaScan
1.1 - Company Overview
Company description
- Provider of cancer detection and surgical decision-support technologies based on Cole frequency measurements, including MarginScan for tissue-sparing skin cancer excisions with margin confirmation without histology; nsCanary for real-time biopsy assessment (pancreatic, biliary, lung); Predictive Technology to assess presence, aggressiveness, and metastasis likelihood; and an Electrical Mammogram detecting breast cancer without radiation.
Products and services
- Electrical Mammogram: A radiation-free system using Cole relaxation frequency measurements to detect breast cancer without false positives or negatives, replacing traditional mammography
- MarginScan™: A clinical-grade device enabling dermatologists to perform skin cancer excisions with healthy tissue sparing by electrically assessing Cole Frequency to confirm cancer-free margins without histological assessment
- NsCanary™: A compact device for real-time biopsy assessment, delivering rapid input on cancer presence in biopsy cores for pancreatic, biliary, and lung applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NovaScan
Normunity
HQ: United States
Website
- Description: Provider of precision immuno-oncology medicines focused on immune normalizers—novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normunity company profile →
PanTher Therapeutics
HQ: United States
Website
- Description: Provider of localized cancer therapies leveraging the Sagittari platform to optimize drug dose and duration for high-dose, tumor-targeted treatment with minimal systemic exposure. Offers PTM-101, a clinical-stage candidate delivering high concentrations of paclitaxel to pancreatic tumors via minimally invasive laparoscopy, and exploratory programs for pancreatic, colon, and lung cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PanTher Therapeutics company profile →
Odyssey Therapeutics
HQ: United States
Website
- Description: Provider of precision immunomodulators for inflammatory diseases and oncology medicines for cancer, enabled by a drug hunting engine combining machine learning, target biology, and medicinal chemistry. Offers target biology and discovery with CRISPR-based screening and advanced cell culture, proprietary small-molecule libraries, and predictive/data sciences.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Odyssey Therapeutics company profile →
Chinook Therapeutics
HQ: Canada
Website
- Description: Provider of precision medicines for kidney diseases, leveraging novel translational platforms and patient stratification tools. Pipeline includes Atrasentan, a selective ETA receptor antagonist in phase 3 for IgA nephropathy and phase 2 for other proteinuric glomerular diseases; Zigakibart (BION-1301), an anti-APRIL monoclonal antibody in phase 3 and phase 1/2 for IgA nephropathy; and CHK-336, an oral LDHA inhibitor in phase 1 for primary and idiopathic hyperoxaluria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chinook Therapeutics company profile →
Living Pharma
HQ: United States
Website
- Description: Provider of Personalized CAR T Cell Therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Living Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NovaScan
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NovaScan
2.2 - Growth funds investing in similar companies to NovaScan
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NovaScan
4.2 - Public trading comparable groups for NovaScan
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →